Valuation: Pulmatrix, Inc.

Market Cap 5.99M 5.24M 4.84M 4.52M 8.51M 566M 8.7M 58.26M 22.49M 279M 22.49M 22M 970M P/E 2024
-2.67x
P/E 2025 -1.58x
Enterprise Value 1.9M 1.67M 1.54M 1.44M 2.7M 180M 2.76M 18.5M 7.14M 88.7M 7.14M 6.99M 308M EV / Sales 2024
2.05x
EV / Sales 2025 -
Free-Float
99.26%
Yield 2024 *
-
Yield 2025 -
1 day-2.44%
1 week+3.90%
Current month+15.11%
1 month+15.11%
3 months+30.08%
6 months-27.93%
Current year-28.25%
1 week 1.44
Extreme 1.44
1.72
1 month 1.22
Extreme 1.22
1.72
Current year 1.16
Extreme 1.16
3.4
1 year 1.16
Extreme 1.16
7.2
3 years 1.16
Extreme 1.16
10.4
5 years 1.16
Extreme 1.16
21.2
10 years 1.16
Extreme 1.16
1,396
Manager TitleAgeSince
Chief Executive Officer 70 20/07/2024
Director TitleAgeSince
Director/Board Member 58 01/11/2019
Director/Board Member 57 23/06/2020
Director/Board Member 55 01/10/2020
Date Insider Type Main position Quantity % Market Cap.
26/01/23Free

Chief Executive Officer

34,900 0.9590%
26/01/23Free

Chief Technology Officer

11,400 0.3133%
26/01/23Free

Director

1,700 0.0467%
Change 5-day change 1-year change 3-year change Capi.($)
-2.44%+3.90%-76.81%-41.39% 5.99M
+0.13%-1.33%+67.18%+121.93% 55.63B
+6.76%+22.83%+91.66%+101.42% 52.25B
+2.25%+3.45%-12.36%-12.80% 23.07B
+0.52%+5.48%+3.34%+411.84% 22.41B
+6.78%+14.47%+40.28%-6.67% 17.32B
+0.97%+3.81%+30.68%-32.21% 15.94B
-0.70%+5.90%+23.38%+186.81% 13.77B
+9.96%+19.81%+157.65%+320.70% 13.47B
+4.21%+4.76%+33.21% - 12.43B
Average +2.85%+7.39%+35.82%+116.63% 22.63B
Weighted average by Cap. +3.25%+7.62%+54.62%+127.54%

Financials

2024 2025
Net sales 7.81M 6.83M 6.31M 5.89M 11.09M 738M 11.34M 75.93M 29.31M 364M 29.31M 28.67M 1.26B -
Net income -9.56M -8.37M -7.73M -7.22M -13.58M -904M -13.89M -92.98M -35.9M -446M -35.9M -35.11M -1.55B -5.16M -4.52M -4.17M -3.9M -7.33M -488M -7.5M -50.21M -19.38M -241M -19.39M -18.96M -836M
Net Debt -9.52M -8.34M -7.7M -7.19M -13.53M -900M -13.84M -92.61M -35.75M -444M -35.76M -34.97M -1.54B -4.09M -3.58M -3.3M -3.09M -5.81M -386M -5.94M -39.77M -15.35M -191M -15.35M -15.02M -662M
Logo Pulmatrix, Inc.
Pulmatrix, Inc. is a biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs.
Employees
2
Date Price Change Volume
29/06/26 $1.600 -2.44% 18,480
26/06/26 $1.640 -1.80% 27,449
25/06/26 $1.670 +9.15% 148,369
24/06/26 $1.530 +2.00% 28,346
23/06/26 $1.500 -2.60% 52,872
  1. Stock Market
  2. Stocks
  3. PULM Stock